Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Short Term Corporate Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.79 (market cap $129.94B), while Vanguard Short Term Corporate Bond ETF trades at $78.57. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | VCSH | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Fixed Income |
52-Week High | $65.89 | $80.20 |
52-Week Low | $42.60 | $78.41 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
VCSH trades at $78.59 with minimal daily movement (+0.13%). Technical indicators show a bearish trend with all moving averages signaling sell, though oscillators remain neutral. The ETF maintains a 4.8% yield but faces headwinds from tight credit spreads and an unattractive entry point according to recent analysis. Recent institutional activity shows mixed sentiment with both position increases and decreases.
The outlook remains cautious with limited upside potential due to current rate environment and credit spread compression. Key risks include interest rate sensitivity and competitive pressure from treasury-focused alternatives. Investors seeking short-term corporate bond exposure should monitor credit quality and duration management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
